Sanofi (SNYNF)

OTCMKTS · Delayed Price · Currency is USD
100.19
+5.16 (5.43%)
Oct 16, 2025, 2:32 PM EDT
5.43%
Market Cap122.66B
Revenue (ttm)53.71B
Net Income (ttm)10.72B
Shares Outn/a
EPS (ttm)8.65
PE Ratio11.44
Forward PE10.77
Dividendn/a
Ex-Dividend Daten/a
Volume454
Average Volume10,875
Open98.29
Previous Close95.03
Day's Range98.29 - 100.19
52-Week Range90.05 - 122.03
Beta0.44
RSI57.29
Earnings DateOct 24, 2025

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange OTCMKTS
Ticker Symbol SNYNF
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

News

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ: SNY) Rezurock (belumosudil). The French drug maker ...

1 day ago - Benzinga

Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia

Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia

1 day ago - GuruFocus

Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD

Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD

2 days ago - GuruFocus

Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...

2 days ago - Benzinga

Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...

2 days ago - GlobeNewsWire

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for ...

2 days ago - GlobeNewsWire

Genzyme Ireland Ltd, the Irish arm of biopharma giant Sanofi, pays out 800m dividend as profits soar to over 328m

The main Irish arm of biopharma giant Sanofi last year paid out dividends of 800m.

2 days ago - Independent Ireland

EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi

CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a ...

3 days ago - PRNewsWire

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...

4 days ago - Benzinga

ITM Appoints Annette Breunig as Chief People Officer

Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Peop...

6 days ago - GlobeNewsWire

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.

9 days ago - Investor's Business Daily

Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy

Sanofi (SNY) stock is in focus as its AlphaMedix therapy developed with Orano Med succeeds in a mid-stage trial for neuroendocrine tumors. Read more here.

11 days ago - Seeking Alpha

BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform

TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.

11 days ago - Business Wire

Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment

(RTTNews) - Sanofi SA (SNY, SNYNF, SAN.PA) announced promising results from its ALPHAMEDIX-02 Phase 2 clinical trial evaluating AlphaMedix (212Pb-DOTAMTATE), a novel somatostatin receptor-targeted alp...

11 days ago - Nasdaq

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

11 days ago - GlobeNewsWire

Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M

Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M

11 days ago - GuruFocus

Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax

Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax

12 days ago - GuruFocus

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...

12 days ago - Benzinga

Bullish Two Hundred Day Moving Average Cross - SNY

In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $50.89, changing hands as high as $51.05 per share. Sanofi shares are currently trading up about 1.7%...

15 days ago - Nasdaq

Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay

Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay

17 days ago - GuruFocus

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...

17 days ago - Business Wire

Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices

Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices

18 days ago - GuruFocus